Press Release

The CAP recognizes the continued excellence of SkylineDx’ accredited laboratory

ROTTERDAM (the Netherlands), SAN DIEGO (California, US), November 9, 2021: today, SkylineDx announced that the Accreditation Committee of the College of American Pathologists (CAP) has renewed accreditation to SkylineDx’ laboratory in San Diego, California (US), based on results of a recent on-site inspection. The CAP advised the facility’s laboratory director, Matthew McGinniss MS, Ph.D., of this national recognition and congratulated for the excellence of the laboratory services provided. SkylineDx is one of nearly 8,000 CAP-accredited facilities worldwide.

The US federal government recognizes the CAP Laboratory Accreditation Program as being equal-to or more-stringent-than the government’s own inspection program. During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.

“Our team in San Diego did an incredible job throughout this entire process, not only anticipating CAP’s on-site inspection, but also working diligently to obtain Pennsylvania and Rhode Island clinical laboratory permits, signifying that SkylineDx’ lab in San Diego is authorized to receive and process specimens from these states”, comments Dharminder Chahal, CEO SkylineDx, “all steps taken are focused on further solidifying our position in the US diagnostics market”. “We are extremely proud of the excellent service that our molecular laboratory provides to patients and clinicians”, concludes Dr. McGinniss.

About SkylineDx

SkylineDx is a biotechnology company, focused on research & development of molecular diagnostics in oncology and inflammatory diseases. The company is headquartered in Rotterdam (the Netherlands) and complemented with a field medical and scientific affairs team in the US and a CAP/CLIA certified laboratory in San Diego (California). SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predict a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. To learn more, please visit www.skylinedx.com.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, please visit www.cap.org.

***

Our news

The CAP recognizes the continued excellence of SkylineDx’ accredited laboratory

ROTTERDAM (the Netherlands), SAN DIEGO (California, US), November 9, 2021: today, SkylineDx announced that the Accreditation Committee of the College of American Pathologists (CAP) has renewed accreditation to

SkylineDx and Imperial College London sign global patent license agreement for Kawasaki Disease

ROTTERDAM (the Netherlands), SAN DIEGO (US), October 12, 2021: today, SkylineDx announced it has entered into an exclusive patent license agreement with Imperial College London for the worldwide development and commercialization of a

SkylineDx commits to develop diagnostic test for Squamous Cell Carcinoma

ROTTERDAM (the Netherlands), SAN DIEGO (US), June 24, 2021: Today, SkylineDx announced to invest in research and development in the field of Squamous Cell Carcinoma (SCC), as part of a Dutch consortium including the Erasmus MC Cancer

Launch US prospective melanoma trial to validate Merlin Assay

ROTTERDAM (the Netherlands), SAN DIEGO (US), June 10, 2021: Today, SkylineDx announced that the first hospitals will start including melanoma patients in a large prospective clinical study in the United States, to validate the Merlin Assay.

Performance Merlin Assay confirmed in independent US validation cohort

ROTTERDAM (the Netherlands), SAN DIEGO (US), April 30, 2021: SkylineDx announced that the performance of their melanoma diagnostic test (Merlin Assay) is confirmed in an independent group of U.S. patients from the Mayo Clinic and West

SkylineDx and Biocartis Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™

ROTTERDAM (the Netherlands), SAN DIEGO (US), April 22, 2021: SkylineDx and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announce the signing of a new partnership agreement which targets

SkylineDx further expands its footprint in the United States

ROTTERDAM (the Netherlands), SAN DIEGO (US), March 23, 2021: SkylineDx received the first Merlin Assay clinical test requests and therefore reported initial gross sales ahead of the commercial launch at the World Congress of Melanoma (WCM)

SkylineDx, Oncode Institute and Utrecht Holdings sign license agreement for innovative algorithm RAINFOREST

ROTTERDAM (The Netherlands) and SAN DIEGO (US), February 23, 2021: today, SkylineDx announces to have signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm RAINFOREST. This

SkylineDx achieves new milestone with ISO 13485:2016 certification

ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 18, 2021: today, SkylineDx announced that it received the esteemed ISO 13485:2016 Quality Management System certificate from notified body BSI Netherlands, after their successful audit

Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence

ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 15, 2021: today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer) at

SkylineDx inks collaboration agreement with Imperial College London and UCSD on diagnostic test Kawasaki Disease

ROTTERDAM (the Netherlands), SAN DIEGO (US), LONDON (UK), September 10, 2020: SkylineDx, announces a collaboration agreement with Professor Michael Levin’s group at Imperial College London and Professor Jane Burns’ group at

How the Dutch resume elective surgery in melanoma after COVID delays

ROTTERDAM (the Netherlands) and SAN DIEGO (US), August 26, 2020: SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to manage

SkylineDx signs 10th collaboration agreement under Falcon Melanoma R&D Program

ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate both melanoma

Prognostic model reveals high-risk melanoma patients that need a clinical trial

ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 14, 2020: SkylineDx announces the publication of two ASCO abstracts describing a biomarker that identifies a subgroup of skin cancer (cutaneous melanoma) patients that could benefit from

Private health insurance reimburses MMprofiler with SKY92 for patients United Kingdom

ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 12, 2020: Everything Genetic Ltd has partnered with a leading private health insurance company in the UK to design an access strategy for patients with multiple myeloma (blood cancer) to

SkylineDx launches melanoma test in United States to support cancer care

ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 22, 2020: SkylineDx announced today that the Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from their CAP/CLIA lab in San

Skin cancer test reduces need for surgery

ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 15, 2020: SkylineDx in collaboration with the Mayo Clinic published yesterday its first study describing a diagnostic test that could reduce up to 42% of surgical interventions used to

SkylineDx and BioInvent to collaborate on patient stratification to maximize impact of treatment with BI-1206

ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 24, 2020: SkylineDx today announces an agreement with BioInvent International AB (OMXS: BINV) to characterize the gene expression and immunological signatures in tumors of patients pre-

National Research Cancer Institute UK confirms benefit molecular profiling in multiple myeloma

ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 17, 2020: multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches, including lenalidomide

First German hospital to implement MMprofiler (SKY92) in real-world setting

ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 4, 2020: SkylineDx is excited to announce the scientific collaboration with the Multiple Myeloma (blood cancer) specialized department of the Wuerzburg University Medical Center II

SkylineDx confirms positive results first independent validation skin cancer test

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 30, 2019: SkylineDx announced, during the European Society for Medical Oncology congress (Barcelona, EU), that it successfully validated the performance of their skin cancer

SkylineDx and Mayo Clinic collaborate on implementing skin cancer test in clinical practice

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 24, 2019: SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester (MN, US) the launch of a pilot study it will conduct with the

Combination of multiple myeloma diagnostics finds lenalidomide benefit

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 12, 2019: fast-progressing multiple myeloma (blood cancer) patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when treated with

03 September 2019 FD release

Translation of Dutch newspaper (Het Financieele Dagblad) article written by Thieu Vaessen. Source can be found via this link. *** Van Herk puts € 20 million into diagnostics company for skin cancer The

Dutch company receives EUR 20 million for skin cancer diagnostic test

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 2, 2019: Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing

UK Commercialization Partner for Multiple Myeloma Diagnostics

ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 25th, 2019: hematologists and multiple myeloma (blood cancer) patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the

Dutch Hospital First to Use Multiple Myeloma Diagnostic Test

ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 23rd, 2019: the academic hematology department of Erasmus Medical Center (EMC) is globally the first hospital to offer every multiple myeloma (blood cancer) patient an innovative

Erasmus MC biedt als eerste test aan bij multipel myeloom

ROTTERDAM en SAN DIEGO (Verenigde Staten), 23 juli 2019: de hematologie afdeling van het Erasmus Medisch Centrum (EMC) is wereldwijd het eerste ziekenhuis dat elke multipel myeloom (bloedkanker) patiënt een innovatieve diagnostische

Dutch scale-up SkylineDx secures respected CAP/CLIA certification for US laboratory

ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 26th, 2019: the Rotterdam headquartered diagnostics company has been granted CAP (College of American Pathologists) accreditation, following its CLIA (Clinical Laboratory Improvement

Study Results Show Significant Improvement Multiple Myeloma Care

ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 13th, 2019: a substantial number of blood cancer (multiple myeloma) patients could make more informed decisions on their treatment if more information becomes available for them and their

Studieresultaten Tonen Significante Verbetering Multipel Myeloom Zorg

ROTTERDAM en SAN DIEGO (Verenigde Staten), 13 juni 2019: een aanzienlijk aantal bloedkanker (multipel myeloom) patiënten kunnen beter beslissen over een behandeling als er meer informatie over hun diagnose beschikbaar komt voor hen en

Dutch Multiple Myeloma Diagnostic Able To Guide Treatment

ROTTERDAM (the Netherlands) and SAN DIEGO (US), November 28, 2018: an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk

Dutch government grants €2.7M for development skin cancer test

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 27, 2018: Netherlands Enterprise Agency (“Rijksdienst voor Ondernemend Nederland”), a part of the Ministry of Economic Affairs and Climate Policy, grants through a

Nederlandse overheid financiert € 2,7M voor ontwikkeling huidkankertest

ROTTERDAM en SAN DIEGO (USA), 27 september, 2018: Rijksdienst voor Ondernemend Nederland (RVO), een onderdeel van het ministerie van Economische Zaken en Klimaat, kent, middels Innovatiekrediet, € 2,7 miljoen toe aan de ontwikkeling van

Groundbreaking algorithm predicts best treatment for cancer patient

ROTTERDAM, the Netherlands and SAN DIEGO USA, July 30th, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURE [1] that links individual cancer patients to

Baanbrekend algoritme voorspelt beste behandeling kankerpatiënt

ROTTERDAM en SAN DIEGO (USA), 30 juli, 2018: Wetenschappelijk tijdschrift Nature Communications publiceerde 27 juli 2018 het onderzoekspaper van Joske Ubels over het GESTURE [1] algoritme dat individuele kankerpatiënten koppelt aan een

Machine learning algorithm predicts treatment response in MM

ROTTERDAM, the Netherlands and SAN DIEGO, USA, August 1, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels about a novel machine learning concept that derives predictive

SkylineDx Poster Presentations at EHA Meeting Further Validate Use of MMprofilerTM with SKY92 in Multiple Myeloma

SKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients RNA-Seq based risk stratification in Multiple Myeloma patients validates SKY92 as a high-risk marker in the

SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma

Rotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the

SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler with SKY92 in Multiple Myeloma

First Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial

SKY92 Gene Signature Facilitates Cost-effective, Risk-stratified Treatment of Multiple Myeloma

Poster Presentation at ISPOR European Congress Demonstrates Cost-savings and HealthGenerating Benefits of SKY92 Rotterdam, the Netherlands and Laguna Hills, CA, November 13, 2017 – SkylineDx announced new data from the 20th

SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial

ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today

SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)

Clinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS) Rotterdam, the Netherlands and Laguna Hills, CA, July 25, 2017 – SkylineDx today announced the

SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

Presentation at BioSB 2017 Demonstrated Value of GESTURE™ for Identifying Patient Subgroups Likely to Benefit from Anti-Cancer Treatment Rotterdam, the Netherlands and Laguna Hills, CA, April 10, 2017 – SkylineDx

SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma

New Studies Demonstrate Value of Gene Expression Risk Profiling to Identify Ultra-High-Risk Multiple Myeloma Patients Rotterdam, the Netherlands and Laguna Hills, CA, November 29, 2016 – SkylineDx today announced the

SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan

The Japanese Patent Office Has Notified SkylineDx of the Decision to Grant a Patent for the SKY92 Gene Signature Rotterdam, the Netherlands, Laguna Hills, CA, Tokyo, Japan, October 11, 2016 - SkylineDx is pleased to announce

SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission

Project Focuses on Development of Gene Expression Profiling Tool to Predict Treatment Outcomes for Patients with Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 4, 2016 - SkylineDx today announced

SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)

Studies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016 - SkylineDx today announced the

SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., March 8, 2016 -- SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma Foundation (IMF) to

SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting

Studies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD

SkylineDx Receives CE-IVD Mark for MMprofiler™ -- Its Innovative Gene Signature-Based Test for Multiple Myeloma

CE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD

SKY92-ISS Superior to current markers in risk classification for myeloma survival

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at

SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO

Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product Rotterdam, The Netherlands, 19 August 2015 - SkylineDx, a

More Accurate Prediction on Prognosis in Multiple Myeloma (bone marrow cancer)

Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the

SkylineDx Presents an Abstract on Risk Identification for Multiple Myeloma Patients at the 20th Congress of the EHA

Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple Myeloma (MM) patients and the clinical